Compounds > letrozole
Page last updated: 2024-10-30

letrozole and Musculoskeletal Pain

letrozole has been researched along with Musculoskeletal Pain in 6 studies

Musculoskeletal Pain: Discomfort stemming from muscles, LIGAMENTS, tendons, and bones.

Research Excerpts

ExcerptRelevanceReference
"Women with stage I-III breast cancer starting adjuvant letrozole and 25(OH)D level ≤40 ng/ml were eligible."9.24Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. ( Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; Nydegger, JL; Reddy, PS; Sharma, P; Yeh, HW, 2017)
"The development of joint pain was similar in the two groups."6.90Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. ( Almstedt, K; Baake, G; Bayer, CM; Beckmann, MW; Brodkorb, T; Brucker, C; Brucker, SY; Fasching, PA; Fehm, T; Fischer, G; Fridman, A; Gass, P; Graf, H; Häberle, L; Hack, CC; Harbeck, N; Hartkopf, AD; Hein, A; Heindl, F; Hoffmann, O; Janni, W; Kohls, A; Kolberg, HC; Krabisch, P; Kuemmel, S; Lindner, C; Loehberg, CR; Lux, MP; Maass, N; Malter, W; Martin, B; Nabieva, N; Pelzer, V; Rack, B; Rauh, C; Rody, A; Schulz, V; Steinfeld-Birg, D; Thomssen, C; Volz, B; Walter, CB; Weigel, M; Wolf, C; Wuerstlein, R, 2019)
"Women with stage I-III breast cancer starting adjuvant letrozole and 25(OH)D level ≤40 ng/ml were eligible."5.24Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. ( Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; Nydegger, JL; Reddy, PS; Sharma, P; Yeh, HW, 2017)
"Postmenopausal women with an early breast cancer scheduled to start adjuvant endocrine therapy with an AI or tamoxifen were recruited."3.80Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. ( Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H, 2014)
"Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment - e."2.94Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. ( Almstedt, K; Baake, G; Bayer, CM; Beckmann, MW; Brodkorb, T; Brucker, C; Brucker, SY; Fasching, PA; Fehm, T; Fischer, G; Fridman, A; Gass, P; Graf, H; Häberle, L; Hack, CC; Harbeck, N; Hartkopf, AD; Hein, A; Heindl, F; Hoffmann, O; Janni, W; Kohls, A; Kolberg, HC; Krabisch, P; Kuemmel, S; Lindner, C; Loehberg, CR; Lux, MP; Maass, N; Malter, W; Martin, B; Nabieva, N; Pelzer, V; Rack, B; Rauh, C; Rody, A; Schulz, V; Steinfeld-Birg, D; Thomssen, C; Volz, B; Walter, CB; Weigel, M; Willer, L; Wolf, C; Wuerstlein, R, 2020)
"The development of joint pain was similar in the two groups."2.90Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. ( Almstedt, K; Baake, G; Bayer, CM; Beckmann, MW; Brodkorb, T; Brucker, C; Brucker, SY; Fasching, PA; Fehm, T; Fischer, G; Fridman, A; Gass, P; Graf, H; Häberle, L; Hack, CC; Harbeck, N; Hartkopf, AD; Hein, A; Heindl, F; Hoffmann, O; Janni, W; Kohls, A; Kolberg, HC; Krabisch, P; Kuemmel, S; Lindner, C; Loehberg, CR; Lux, MP; Maass, N; Malter, W; Martin, B; Nabieva, N; Pelzer, V; Rack, B; Rauh, C; Rody, A; Schulz, V; Steinfeld-Birg, D; Thomssen, C; Volz, B; Walter, CB; Weigel, M; Wolf, C; Wuerstlein, R, 2019)
"Additionally, breast cancer patients with new onset or worsening of pain over the study period had a significantly smaller change in mean DHEAS concentration from baseline to 3 months (P = 0."2.76Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. ( Gallicchio, L; Helzlsouer, KJ; Macdonald, R; Rushovich, E; Wood, B, 2011)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Hack, CC2
Häberle, L2
Brucker, SY2
Janni, W2
Volz, B2
Loehberg, CR2
Hartkopf, AD2
Walter, CB2
Baake, G2
Fridman, A2
Malter, W2
Wuerstlein, R2
Harbeck, N2
Hoffmann, O2
Kuemmel, S2
Martin, B2
Thomssen, C2
Graf, H2
Wolf, C2
Lux, MP2
Bayer, CM2
Rauh, C2
Almstedt, K2
Gass, P2
Heindl, F2
Brodkorb, T2
Willer, L1
Lindner, C2
Kolberg, HC2
Krabisch, P2
Weigel, M2
Steinfeld-Birg, D2
Kohls, A2
Brucker, C2
Schulz, V2
Fischer, G2
Pelzer, V2
Rack, B2
Beckmann, MW2
Fehm, T2
Rody, A2
Maass, N2
Hein, A2
Fasching, PA2
Nabieva, N2
Khan, QJ1
Kimler, BF1
Reddy, PS1
Sharma, P1
Klemp, JR1
Nydegger, JL1
Yeh, HW1
Fabian, CJ1
Kyvernitakis, I1
Ziller, V1
Hars, O1
Bauer, M1
Kalder, M1
Hadji, P1
Lintermans, A1
Vanderschueren, D1
Verhaeghe, J1
Van Asten, K1
Jans, I1
Van Herck, E1
Laenen, A1
Paridaens, R1
Billen, J1
Pauwels, S1
Vermeersch, P1
Wildiers, H1
Christiaens, MR1
Neven, P1
Gallicchio, L1
Macdonald, R1
Wood, B1
Rushovich, E1
Helzlsouer, KJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Light Emitting Diode for the Treatment of Genitourinary Syndrome of Menopause Associated With Hormonal Therapy for Treating Breast Cancer: Randomized Controlled Clinical Trial[NCT03833726]77 participants (Actual)Interventional2019-01-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

5 trials available for letrozole and Musculoskeletal Pain

ArticleYear
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
    Breast (Edinburgh, Scotland), 2020, Volume: 50

    Topics: Aged; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Complementary Therapies; Female; Germany;

2020
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
    Breast cancer research and treatment, 2017, Volume: 166, Issue:2

    Topics: Administration, Oral; Bone Density Conservation Agents; Breast Neoplasms; Calcium, Dietary; Chemothe

2017
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
    International journal of cancer, 2019, 10-15, Volume: 145, Issue:8

    Topics: Aged; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Mu

2019
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
    Climacteric : the journal of the International Menopause Society, 2014, Volume: 17, Issue:3

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Anxiety; Aromatase Inhibitors; Breast Neoplasms;

2014
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
    Breast cancer research and treatment, 2011, Volume: 130, Issue:2

    Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Bre

2011

Other Studies

1 other study available for letrozole and Musculoskeletal Pain

ArticleYear
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromat

2014